Publication Name	World Journal of Gastroenterology
Manuscript ID	2715
Country	Italy

Received	2013-03-11 08:44
Peer-Review Started	2013-03-12 12:33
To Make the First Decision	2013-04-16 08:57
Return for Revision	2013-04-17 13:48
Revised	2013-05-27 02:20
Second Decision	2013-06-03 16:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-04 09:34
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-09 09:58
Publish the Manuscript Online	2013-08-27 16:46

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review
Manuscript Source	Invited Manuscript
All Author List	Roberta Caccaro, Edoardo Savarino, Renata D’Incà and Giacomo Carlo Sturniolo
Funding Agency and Grant Number
Corresponding Author	Roberta Caccaro, MD, Department of Surgical, Oncological and Gastroenterological Sciences, Gastroenterology Section, University of Padua, Via Giustiniani 2, 35128 Padova, Italy. roberta.caccaro@gmail.com
Key Words	Interstitial lung disease; Crohn’s disease; Infliximab; Mesalamine; Drug-induced toxicity
Core Tip	Safety during anti-tumor necrosis factor (TNF)-α therapy is a major concern. Paradoxical inflammatory and autoimmune phenomena can be induced by this treatment and should always be considered. Interstitial lung disease is an emerging complication often observed early after the beginning of treatment, particularly when combination immunosuppressive regimens are employed. This case demonstrates that interstitial lung disease can also occur later during anti-TNF-α treatment and during monotherapy. Thus, great vigilance is recommended when patients start complaining of any respiratory symptom.
Publish Date	2013-08-27 16:46
Citation	Caccaro R, Savarino E, D’Incà R, Sturniolo GC. Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review. World J Gastroenterol 2013; 19(32): 5377-5380
URL	http://www.wjgnet.com/1007-9327/full/v19/i32/5377.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i32.5377

Full Article (PDF)	WJG-19-5377.pdf
Manuscript File	2715-Review.doc
Answering Reviewers	2715-Answering reviewers.pdf
Copyright License Agreement	2715-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	2715-Language certificate.pdf
Peer-review Report	2715-Peer review.pdf
Scientific Editor Work List	2715-Scientific editor work list.doc